Top Tweets for #MONARCHE

8 months ago

9 Breast Ca studies that we touched on with @VKaklamani for #ESMO25: ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 #OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert

OncBrothers's tweet photo. 9 Breast Ca studies that we touched on with @VKaklamani for #ESMO25:

✅ #monarchE & #NATALEE
✅ #VIKTORIA1
✅ #evERA
✅ #DESTINYBreast: 05/09/11
✅ #ASCENT03
✅ #TropionBreast02

#OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert https://t.co/6aT4Mtwaxk

8 months ago

Breast Ca Highlights from #ESMO25 w/ @VKaklamani! ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 Full Discussion: - https://t.co/bYNsRGS2hh - Also on “Oncology Brothers” podcast #OncTwitter #bcsm

2

34

16

19

27K

0

151

75

64

32K

Bishal Gyawali, MD, PhD, FASCO

8 months ago

Breast Ca Highlights from #ESMO25 w/ @VKaklamani! ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 Full Discussion: - https://t.co/bYNsRGS2hh - Also on “Oncology Brothers” podcast #OncTwitter #bcsm

2

34

16

19

27K

@oncology_bg

9 months ago

Best of #breastcancer news from #ESMO25? Watch this video and that’ll be enough. We cover all these trials: Positive #MonarchE and #NATALEE #Destiny Breast 11 and DB 05 evera and #VIKTORIA1 #ASCENT03 and #TropionBreast02 #SONIA https://t.co/l17z2nfG8N

0

9

3

2

2K

Bishal Gyawali, MD, PhD, FASCO

@oncology_bg

9 months ago

Looking to catch up on major highlights from #ESMO25 with critical commentary but without the hype? Watch this video where I cover the major takeaways from the meeting. https://t.co/zyMoaCom9o I discuss these studies- Breast Positive #MonarchE and #NATALEE #Destiny Breast 11 and DB 05 evera and #VIKTORIA1 #ASCENT03 and #TropionBreast02 #SONIA GU Keynote 905 #ALBAN and #POTOMAC #PSAMAddition #EMBARK DV plus Toripalimab #IMVigor011 Lung #PAULIEN Sacituzumab GI #Dynamic3 #Matterhorn #Stellar303 Others CM 238 and NADINA RARImmune

0

13

5

6

3K

OncUpdates

@OncUpdates

9 months ago

#ESMO25 Highlights! Halfway there! 1️⃣ #DESTINY-Breast11 2️⃣ #DESTINY-Breast05 3️⃣ #monarchE 4️⃣ #NATALEE 5️⃣ #VIKTORIA-1 6️⃣ #KEYNOTE905 #MedTwitter #Oncology #OncTwitter #MedX #CommunityOncology #MedEd #bcsm Read more on top abstract highlights⬇️ https://t.co/vzDJoV8rfU

1

2

1

0

317

Erika Hamilton, MD, FASCO @ErikaHamilton9

9 months ago

#monarchE ki-67 analysis by Prof Martin 📍Many patients (3/4) w/ high ki67 up front convert to low after NAC. 💡 Those that convert to low ki-67 have better outcome, but less so than those that are low initially 🔑Benefit of abema regardless of ki-67 #ESMO25 #ESMOAmbassadors

ErikaHamilton9's tweet photo. #monarchE ki-67 analysis by Prof Martin

📍Many patients (3/4) w/ high ki67 up front convert to low after NAC.

💡 Those that convert to low ki-67 have better outcome, but less so than those that are low initially

🔑Benefit of abema regardless of ki-67

#ESMO25 #ESMOAmbassadors https://t.co/6hyC8FIXbo

1

21

7

10

2K

Targeted Oncology @TargetedOnc

9 months ago

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone. #monarchE #ESMO25 https://t.co/WxGVYq73Tu

3

1

0

346

9 months ago

The #OncoalertTopTweet DAY One #ESMO25 Our🚨Faculty @delmastro_lucia discussing the results of #monarchE #BreastCancer Presentati a #ESMO25 i risultati aggiornati dello studio monarchE che dimostrano come abemaciclib nel trattamento adiuvante delle pazienti con carcinoma mammario ER+ ad alto rischio induce un vantaggio in sopravvivenza globale #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @matteolambe @Icro_Meattini

9 months ago

Dear Colleagues at #ESMO25 An honor to introduce our @OncoAlert 🚨Faculty @delmastro_lucia 🇮🇹 discussing the results of #monarchE 🦋 in #BreastCancer Presentati a #ESMO25 i risultati aggiornati dello studio monarchE che dimostrano come abemaciclib nel trattamento adiuvante delle pazienti con carcinoma mammario ER+ ad alto rischio induce un vantaggio in sopravvivenza globale @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

1

26

17

0

11K

1

12

5

0

1K

Erika Hamilton, MD, FASCO @ErikaHamilton9

9 months ago

2. #monarchE: Adj Abemaciclib (approved in Oct 2021) for high risk HR+, LN+ breast cancer, 150mg BID + ET for 2 yrs. - 7yr IDFS: 77.4% vs. 70.9% - 7yr DRFS: 80% vs. 74.9% ⭐️ OS: 15.8% ⬇️ risk of death (HR: 0.84). ~2% delta in ITT OS 4/12

OncBrothers's tweet photo. 2. #monarchE: Adj Abemaciclib (approved in Oct 2021) for high risk HR+, LN+ breast cancer, 150mg BID + ET for 2 yrs.

- 7yr IDFS: 77.4% vs. 70.9%
- 7yr DRFS: 80% vs. 74.9%
⭐️ OS: 15.8% ⬇️ risk of death (HR: 0.84). ~2% delta in ITT OS

4/12 https://t.co/BZBM54TZWP

9 months ago

Prof. Johnston presents OS for #monarchE Median f/u 6.3 yrs (all pts off abema 4+ yrs) 👏 we now have OS. 301 vs. 360 deaths - survival 1.8% ⬆️ 7 yrs (was 1% at 5, 1.3% at 6) Still more 👩🏾 👧🏼 alive with metastatic dz in ET alone iDFS 6.5% now #ESMO25 #ESMOAmbassadors

ErikaHamilton9's tweet photo. Prof. Johnston presents OS for #monarchE

Median f/u 6.3 yrs (all pts off abema 4+ yrs)

👏 we now have OS. 301 vs. 360 deaths - survival 1.8% ⬆️ 7 yrs (was 1% at 5, 1.3% at 6)

Still more 👩🏾 👧🏼 alive with metastatic dz in ET alone

iDFS 6.5% now

#ESMO25 #ESMOAmbassadors https://t.co/Sv3P2TcaOv

2

35

5

4

5K

3

11

1

2

2K

Andrea Boutros @boutrosand

9 months ago

Day 1 #ESMO25 Highlights: Breast Ca: 1. #POSITIVE 🤰 outcomes 2. #monarchE HR+ Adj Abema 3. #NATALEE HR+ Adj Ribo Lung Ca: 4. #NorthStar Local Rx in mEGFR 5. #FLAURA2 Chemo + Osi in mEGFR 6. #SOHO01 & #BeamionLung01 HER2+ NSCLC 1/12 #OncTwitter @myESMO @OncUpdates

OncBrothers's tweet photo. Day 1 #ESMO25 Highlights:

Breast Ca:
1. #POSITIVE 🤰 outcomes

2. #monarchE HR+ Adj Abema

3. #NATALEE HR+ Adj Ribo

Lung Ca:
4. #NorthStar Local Rx in mEGFR

5. #FLAURA2 Chemo + Osi in mEGFR

6. #SOHO01 & #BeamionLung01 HER2+ NSCLC

1/12

#OncTwitter @myESMO @OncUpdates https://t.co/7omikHvP2N

2

149

63

89

23K

OncUpdates

@OncUpdates

9 months ago

#ESMO2025 Highlights! ⭐️#monarchE 7-Year Analysis-Adjuvant Abemaciclib+ Endocrine Therapy in High-Risk HR+/HER2- Early Breast Cancer ✅️OS: HR 0.84 ✅️7-yr IDFS: 77.4 vs 70.9% ✅7-year IDFS: 77.4 vs 70.9% 🌊 First adjuvant CDK4/6i showing an OS advantage #MedTwitter #MedX

OncUpdates's tweet photo. #ESMO2025 Highlights!

⭐️#monarchE 7-Year Analysis-Adjuvant Abemaciclib+ Endocrine Therapy in High-Risk HR+/HER2- Early Breast Cancer

✅️OS: HR 0.84
✅️7-yr IDFS: 77.4 vs 70.9%
✅7-year IDFS: 77.4 vs 70.9%

🌊 First adjuvant CDK4/6i showing an OS advantage
#MedTwitter #MedX https://t.co/nTxBu0RCWQ

1

2

1

2

366

9 months ago

Fantastic @delmastro_lucia discussing the fresh results from the #MonarchE update 🦋 here in Berlin #ESMO25 🇮🇹

Kristina Jankovic, MD @JankovicK

9 months ago

Dear Colleagues at #ESMO25 An honor to introduce our @OncoAlert 🚨Faculty @delmastro_lucia 🇮🇹 discussing the results of #monarchE 🦋 in #BreastCancer Presentati a #ESMO25 i risultati aggiornati dello studio monarchE che dimostrano come abemaciclib nel trattamento adiuvante delle pazienti con carcinoma mammario ER+ ad alto rischio induce un vantaggio in sopravvivenza globale @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

1

26

17

0

11K

1

17

9

0

2K

9 months ago

@OncoAlert 🚨Faculty @delmastro_lucia 🇮🇹 presents updated #monarchE results at #ESMO25 🦋 Abemaciclib improves OS in high-risk ER+ #BreastCancer 💡

9 months ago

Dear Colleagues at #ESMO25 An honor to introduce our @OncoAlert 🚨Faculty @delmastro_lucia 🇮🇹 discussing the results of #monarchE 🦋 in #BreastCancer Presentati a #ESMO25 i risultati aggiornati dello studio monarchE che dimostrano come abemaciclib nel trattamento adiuvante delle pazienti con carcinoma mammario ER+ ad alto rischio induce un vantaggio in sopravvivenza globale @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

1

26

17

0

11K

1

9

4

0

1K